Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in scalp, nail, and palmoplantar psoriasis: subgroup analyses of the phase 3 POETYK PSO-1 and PSO-2 trials

Main Article Content

Andrew Blauvelt
Phoebe Rich
Howard Sofen
Jo Lambert
Joseph F Merola
Mark Lebwohl
Thomas Scharnitz
Kim Hoyt
Renata M Kisa
Subhashis Banerjee


deucravacitinib, tyrosine kinase 2 inhibitor, psoriasis




1. SOTYKTU™ (deucravacitinib) [package insert]. Princeton, NJ, USA: Bristol-Myers Squibb Company; September 2022.

2. Burke JR, et al. Sci Transl Med. 2019;11:eaaw1736.

3. Wrobleski ST, et al. J Med Chem. 2019;62:8973-8995.

4. Armstrong AW, et al. J Am Acad Dermatol. 2022;S0190-9622(22)02256-3. doi: 10.1016/j.jaad.2022.07.002. Online ahead of print.

5. Strober B, et al. J Am Acad Dermatol. 2022;S0190-9622(22)02643-3. doi: 10.1016/j.jaad.2022.08.061. Online ahead of print.

6. Warren RB, et al. Presented at the European Academy of Dermatology and Venereology (EADV) Spring Symposium; 12—14 May 2022;
Ljubljana, Slovenia.

Most read articles by the same author(s)

<< < 5 6 7 8 9 10 11 12 13 14 > >>